Animesh Pardanani

40.1k citations

466 papers · 21.6k indexed · 7 hit papers · h-index 78

Genetics top 0.01%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 332
- Hemoglobinopathies and Related Disorders 26
Hematology top 0.01%
- Acute Myeloid Leukemia Research 189
- Chronic Myeloid Leukemia Treatments 156
- Multiple Myeloma Research and Treatments 26
Rheumatology top 0.02%
- Eosinophilic Disorders and Syndromes 142
Immunology top 0.5%
- Mast cells and histamine 71
Molecular Biology top 0.5%
- Kruppel-like factors research 89

Co-authors: Ayalew Tefferi Terra L. Lasho Christy M. Finke Curtis A. Hanson Naseema Gangat Rhett P. Ketterling Ruben A. Mesa Mrinal M. Patnaik
Cited by: Genetics Hematology Rheumatology
Partner nations: United States Italy Canada

In The Last Decade

Animesh Pardanani

443 papers receiving 21.3k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2015 Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
2014 CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
2014 Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
2011 Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
2010 Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
2010 DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
2006 MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

Peers

Countries citing papers authored by Animesh Pardanani

Since Specialization

Citations

This map shows the geographic impact of Animesh Pardanani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Animesh Pardanani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Animesh Pardanani more than expected).

Fields of papers citing papers by Animesh Pardanani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Animesh Pardanani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Animesh Pardanani. The network helps show where Animesh Pardanani may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Animesh Pardanani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Animesh Pardanani Line = papers co-authored together Animesh Pardanani links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases Moazah Iftikhar,Masooma Rana,Yamna Jadoon,Maymona Abdelmagid,Kaaren K. Reichard,Cinthya Zepeda Mendoza,Animesh Pardanani,Ayalew Tefferi,Naseema Gangat	2024	1
2	TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance Ayalew Tefferi,Maymona Abdelmagid,Giuseppe Gaetano Loscocco,Kebede Begna,Aref Al‐Kali,James M. Foran,Jeanne Palmer,Talha Badar,Mrinal M. Patnaik,Kaaren K. Reichard,Rong He,Cinthya Mendoza,Mithun Vinod Shah,Attilio Orazi,Daniel A. Arber,Animesh Pardanani,Alessandro M. Vannucchi,Devendra Hiwase,Naseema Gangat,Paola Guglielmelli	2024	0
3	Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies Naseema Gangat,Amritpal Singh,Rimal Ilyas,Giuseppe Gaetano Loscocco,Michelle A. Elliott,Kebede H. Begna,Animesh Pardanani,Ayalew Tefferi	2024	4
4	PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis Ayalew Tefferi,Saubia Fathima,Ali Alsugair,Fnu Aperna,Anuya Natu,Maymona Abdelmagid,Clifford M. Csizmar,Mark E. Gurney,Terra L. Lasho,Christy M. Finke,Abhishek A. Mangaonkar,Aref Al‐Kali,Animesh Pardanani,Kaaren K. Reichard,Rong He,Naseema Gangat,Mrinal M. Patnaik	2024	2
5	Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent Nickolas Steinauer,Kristen McCullough,Aref Al‐Kali,Hassan B. Alkhateeb,Kebede H. Begna,Abhishek A. Mangaonkar,Antoine N. Saliba,Mehrdad Hefazi,Mark R. Litzow,William J. Hogan,Mithun Vinod Shah,Animesh Pardanani,Talha Badar,Hemant S. Murthy,James M. Foran,Cecilia Y. Arana Yi,Ayalew Tefferi,Naseema Gangat	2023	1
6	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response Kebede H. Begna,Jaya Kittur,Naseema Gangat,Hassan B. Alkhateeb,Mrinal M. Patnaik,Aref Al‐Kali,M. A. Elliott,William J. Hogan,Mark R. Litzow,Animesh Pardanani,Curtis A. Hanson,Rhett P. Ketterling,Ayalew Tefferi	2022	4
7	A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy Ayalew Tefferi,Naseema Gangat,Aref Al‐Kali,Hassan B. Alkhateeb,Mithun Vinod Shah,Mrinal M. Patnaik,Michelle A. Elliott,William J. Hogan,Mark R. Litzow,C. Christopher Hook,Abhishek A. Mangaonkar,David S. Viswanatha,Dong Chen,Animesh Pardanani,Rhett P. Ketterling,Courtney D. DiNardo,Tapan M. Kadia,Farhad Ravandi,Koji Sasaki,Kebede H. Begna	2022	6
8	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients Giuseppe Gaetano Loscocco,Paola Guglielmelli,Naseema Gangat,Elena Rossi,Carmela Mannarelli,Silvia Betti,Chiara Maccari,Francesco Ramundo,Yamna Jadoon,Francesca Gesullo,Sara Ceglie,Chiara Paoli,Animesh Pardanani,Valerio De Stefano,Ayalew Tefferi,Alessandro M. Vannucchi	2021	26
9	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy Kebede H. Begna,Naseema Gangat,Aref Al‐Kali,Mark R. Litzow,William J. Hogan,Mrinal M. Patnaik,Animesh Pardanani,C. Christopher Hook,Alexandra P. Wolanskyj,Michelle A. Elliott,Curtis A. Hanson,Rhett P. Ketterling,Ayalew Tefferi	2021	4
10	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients Erika Morsia,Kristen McCullough,Maansi Joshi,Joselle Cook,Hassan B. Alkhateeb,Aref Al‐Kali,Kebede H. Begna,Michelle A. Elliott,William J. Hogan,Mark R. Litzow,Mithun Vinod Shah,Animesh Pardanani,Mrinal M. Patnaik,Ayalew Tefferi,Naseema Gangat	2020	89
11	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long‐lived patients Domenico Penna,Terra L. Lasho,Christy M. Finke,Rangit Vallapureddy,Curtis A. Hanson,Rhett P. Ketterling,Animesh Pardanani,Naseema Gangat,Ayalew Tefferi	2018	8
12	Mutations and karyotype predict treatment response in myelodysplastic syndromes Damé Idossa,Terra L. Lasho,Christy M. Finke,Rhett P. Ketterling,Mrinal M. Patnaik,Animesh Pardanani,Naseema Gangat,Ayalew Tefferi	2018	21
13	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts Ayalew Tefferi,Mythri Mudireddy,Francesco Mannelli,Kebede H. Begna,Mrinal M. Patnaik,Curtis A. Hanson,Rhett P. Ketterling,Naseema Gangat,Meera Yogarajah,Valerio De Stefano,Francesco Passamonti,Vittorio Rosti,Maria Chiara Finazzi,Alessandro Rambaldi,Alberto Bosi,Paola Guglielmelli,Animesh Pardanani,Alessandro M. Vannucchi	2018	93
14	Myelofibrosis Treatment Algorithm 2018 Ayalew Tefferi,Paola Guglielmelli,Animesh Pardanani,Alessandro M. Vannucchi	2018	30
15	Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms Sangeeta Nischal,Sanchari Bhattacharyya,Maximilian Christopeit,Yiting Yu,Li Zhou,Tushar D. Bhagat,Davendra Sohal,Britta Will,Yongkai Mo,Masako Suzuki,Animesh Pardanani,Michael A. McDevitt,Jaroslaw P. Maciejewski,Ari Melnick,John M. Greally,Ulrich Steidl,Alison R. Moliterno,Amit Verma	2012	42
16	Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Studybreakdown → Ayalew Tefferi,Rakhee Vaidya,Domenica Caramazza,Christy M. Finke,Terra L. Lasho,Animesh Pardanani	2011	435
17	Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis Animesh Pardanani,Jason Gotlib,Catriona Jamieson,Jörge E. Cortes,Moshe Talpaz,Richard M. Stone,Michael H. Silverman,D. Gary Gilliland,Jolene Shorr,Ayalew Tefferi	2011	310
18	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Statusbreakdown → Naseema Gangat,Domenica Caramazza,Rakhee Vaidya,Geeta George,Kebede H. Begna,Susan M. Schwager,Daniel Van Dyke,Curtis A. Hanson,Wenting Wu,Animesh Pardanani,Francisco Cervantes,Francesco Passamonti,Ayalew Tefferi	2010	657
19	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors Ken-Hong Lim,Ayalew Tefferi,Terra L. Lasho,Christy M. Finke,Mrinal M. Patnaik,Joseph H. Butterfield,Rebecca F. McClure,Chin‐Yang Li,Animesh Pardanani	2009	369
20	Bone Marrow Angiogenesis in Systemic Mast Cell Disease Jin-Young Baek,Chin‐Yang Li,Animesh Pardanani,Joseph H. Butterfield,Ayalew Tefferi	2002	6

About Animesh Pardanani

Animesh Pardanani is a scholar working on Genetics, Hematology and Rheumatology, having authored 466 papers that have together received 21.6k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (332 papers), Acute Myeloid Leukemia Research (189 papers), Chronic Myeloid Leukemia Treatments (156 papers), Eosinophilic Disorders and Syndromes (142 papers), Kruppel-like factors research (89 papers), Mast cells and histamine (71 papers), Multiple Myeloma Research and Treatments (26 papers) and Hemoglobinopathies and Related Disorders (26 papers). The work is most often cited by research in Genetics (15.2k citations), Hematology (13.0k citations) and Rheumatology (8.0k citations). Animesh Pardanani has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Ayalew Tefferi, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Naseema Gangat, Rhett P. Ketterling, Ruben A. Mesa, Mrinal M. Patnaik, Kebede H. Begna and Alessandro M. Vannucchi.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact